WASHINGTON — A big legislative package due for renewal later this year could include hundreds of millions of dollars of drug incentives — and the medical community is already jostling to shape its contents.

The Pandemic and All-Hazards Preparedness Reauthorization Act, a 2013 update of a 2006 law, is slated to end in September. It helps fund disaster-response initiatives such as vaccines for smallpox, diagnostic tests for influenza, and hospital programs to treat victims of a nuclear attack.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy